(Updated - May 19, 2020 5:07 AM EDT)

(updating comment)JPMorgan analyst Chris Schott downgraded TherapeuticsMD (NASDAQ: TXMD) from Overweight ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE